Prosight Management as of Dec. 31, 2017
Portfolio Holdings for Prosight Management
Prosight Management holds 29 positions in its portfolio as reported in the December 2017 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
---|---|---|---|---|---|
Allergan | 11.8 | $16M | 98k | 163.58 | |
Macrogenics (MGNX) | 8.5 | $12M | 608k | 19.00 | |
Cidara Therapeutics Inc Common Stock Usd 0.0001 | 8.2 | $11M | 1.6M | 6.80 | |
Eiger Biopharmaceuticals | 7.0 | $9.5M | 679k | 13.95 | |
Sabra Health Care REIT (SBRA) | 5.5 | $7.5M | 402k | 18.77 | |
Centene Corporation (CNC) | 5.3 | $7.2M | 71k | 100.87 | |
Chimerix (CMRX) | 5.0 | $6.8M | 1.5M | 4.63 | |
Achaogen | 4.5 | $6.1M | 571k | 10.74 | |
Uniqure Nv (QURE) | 4.1 | $5.6M | 285k | 19.59 | |
Almost Family | 3.7 | $5.0M | 91k | 55.35 | |
Reata Pharmaceuticals Inc Cl A | 3.6 | $4.9M | 173k | 28.32 | |
Quotient | 3.4 | $4.6M | 933k | 4.95 | |
Ignyta | 3.4 | $4.6M | 171k | 26.70 | |
Iovance Biotherapeutics (IOVA) | 3.0 | $4.1M | 507k | 8.00 | |
Endologix | 2.6 | $3.5M | 656k | 5.35 | |
Radius Health | 2.6 | $3.5M | 110k | 31.77 | |
Paratek Pharmaceuticals | 2.4 | $3.2M | 179k | 17.90 | |
AVEO Pharmaceuticals | 2.2 | $3.0M | 1.1M | 2.79 | |
Nabriva Therapeutics | 2.2 | $2.9M | 491k | 5.98 | |
Clovis Oncology | 2.0 | $2.7M | 40k | 68.00 | |
Bellicum Pharma | 1.9 | $2.5M | 301k | 8.41 | |
Ultragenyx Pharmaceutical (RARE) | 1.5 | $2.1M | 45k | 46.39 | |
Dex (DXCM) | 1.3 | $1.8M | 31k | 57.38 | |
On Assignment | 1.2 | $1.7M | 26k | 64.28 | |
Lipocine | 0.9 | $1.3M | 373k | 3.44 | |
Conformis | 0.7 | $952k | 400k | 2.38 | |
Noveliontherapeuti.. | 0.7 | $925k | 297k | 3.12 | |
Acadia Healthcare (ACHC) | 0.7 | $878k | 27k | 32.62 | |
Adamas Pharmaceuticals | 0.3 | $407k | 12k | 33.92 |